Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Co-administration of deflazacort and doxycycline: a potential pharmacotherapy for Duchenne muscular dystrophy.

Clinical and experimental pharmacology & physiology - 1 Jul 2015

Pereira Juliano Alves, Marques Maria Julia, Santo Neto Humberto

Abstract excerpt

The standard therapy used in the treatment of Duchenne muscle dystrophy (DMD) is corticoids, such as deflazacort and prednisone. However, they have limited therapeutic value, and their combination with drugs already in use to treat other human diseases could potentially increase corticoid outcomes in DMD. In the present study, we evaluated whether a combined therapy of the corticoid deflazacort with doxycycline...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Doxycycline
Share to Drug Combinations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mice, Inbred mdx

Share to Muscle Strength

Share to Muscular Dystrophy, Duchenne

Share to Phenotype

Share to Treatment Outcome

Source

Identifiers

PMID: 25959722
DOI: 10.1111/1440-1681.12417

Genes

DMD
TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Co-administration of deflazacort and doxycycline: a potential pharmacotherapy for Duchenne muscular dystrophy.PMID 25959722Read ↗

Molecular and Biochemical Therapeutic Strategies for Duchenne Muscular DystrophySemantic proximity Read ↗

Emerging drugs for Duchenne muscular dystrophySemantic proximity Read ↗

Enhancement of Prednisolone efficacy and safety in Duchenne muscular dystrophy via neutrophil elastase inhibitionSemantic proximity Read ↗

Doxycycline ameliorates the dystrophic phenotype of skeletal and cardiac muscles in mdx mice.Semantic proximity Read ↗

Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future.Semantic proximity Read ↗

Dystrophic phenotype improvement in the diaphragm muscle of mdx mice by diacerhein.Semantic proximity Read ↗

Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular DystrophySemantic proximity Read ↗

Immunological characterization of a rat model of Duchenne’s disease and demonstration of improved muscle strength after anti-CD45RC antibody treatmentSemantic proximity Read ↗

Pharmacological prospects in the treatment of Duchenne muscular dystrophy.Semantic proximity Read ↗

Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice.Semantic proximity Read ↗

VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.Semantic proximity Read ↗

Muscle Damage in Dystrophic mdx Mice Is Influenced by the Activity of Ca2+-Activated KCa3.1 ChannelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.